ProMIS Neurosciences Competitors

Medicenna Therapeutics (TSE:MDNA) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Medicenna Therapeutics and ProMIS Neurosciences, as reported by MarketBeat.

Valuation and Earnings

This table compares Medicenna Therapeutics and ProMIS Neurosciences' top-line revenue, earnings per share (EPS) and valuation.

Medicenna Therapeutics has higher earnings, but lower revenue than ProMIS Neurosciences. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than ProMIS Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medicenna Therapeutics and ProMIS Neurosciences' net margins, return on equity and return on assets.

Summary

ProMIS Neurosciences beats Medicenna Therapeutics on 3 of the 3 factors compared between the two stocks.

Oncolytics Biotech (TSE:ONC) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Profitability

This table compares Oncolytics Biotech and ProMIS Neurosciences' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for Oncolytics Biotech and ProMIS Neurosciences, as reported by MarketBeat.

Oncolytics Biotech currently has a consensus price target of C$6.00, indicating a potential upside of 20.24%. Given Oncolytics Biotech's higher probable upside, equities research analysts plainly believe Oncolytics Biotech is more favorable than ProMIS Neurosciences.

Earnings & Valuation

This table compares Oncolytics Biotech and ProMIS Neurosciences' revenue, earnings per share (EPS) and valuation.

Oncolytics Biotech has higher earnings, but lower revenue than ProMIS Neurosciences. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Oncolytics Biotech beats ProMIS Neurosciences on 3 of the 5 factors compared between the two stocks.

Emblem (CVE:EMC) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares Emblem and ProMIS Neurosciences' gross revenue, earnings per share (EPS) and valuation.

ProMIS Neurosciences has lower revenue, but higher earnings than Emblem. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Emblem, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Emblem and ProMIS Neurosciences, as reported by MarketBeat.

Profitability

This table compares Emblem and ProMIS Neurosciences' net margins, return on equity and return on assets.

Summary

ProMIS Neurosciences beats Emblem on 3 of the 5 factors compared between the two stocks.

IMV (TSE:IMV) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares IMV and ProMIS Neurosciences' revenue, earnings per share (EPS) and valuation.

ProMIS Neurosciences has lower revenue, but higher earnings than IMV. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IMV and ProMIS Neurosciences' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for IMV and ProMIS Neurosciences, as reported by MarketBeat.

IMV currently has a consensus price target of C$5.08, suggesting a potential upside of 40.42%. Given IMV's higher probable upside, equities research analysts clearly believe IMV is more favorable than ProMIS Neurosciences.

Summary

IMV beats ProMIS Neurosciences on 4 of the 6 factors compared between the two stocks.

Antibe Therapeutics (TSE:ATE) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of recent ratings for Antibe Therapeutics and ProMIS Neurosciences, as provided by MarketBeat.

Antibe Therapeutics currently has a consensus price target of C$7.75, suggesting a potential upside of 58.81%. Given Antibe Therapeutics' higher possible upside, research analysts plainly believe Antibe Therapeutics is more favorable than ProMIS Neurosciences.

Profitability

This table compares Antibe Therapeutics and ProMIS Neurosciences' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Antibe Therapeutics and ProMIS Neurosciences' gross revenue, earnings per share and valuation.

ProMIS Neurosciences has lower revenue, but higher earnings than Antibe Therapeutics. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Antibe Therapeutics beats ProMIS Neurosciences on 4 of the 7 factors compared between the two stocks.

Fennec Pharmaceuticals (TSE:FRX) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Fennec Pharmaceuticals and ProMIS Neurosciences, as provided by MarketBeat.

Profitability

This table compares Fennec Pharmaceuticals and ProMIS Neurosciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Fennec Pharmaceuticals and ProMIS Neurosciences' revenue, earnings per share (EPS) and valuation.

ProMIS Neurosciences has lower revenue, but higher earnings than Fennec Pharmaceuticals. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Fennec Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.